Free Cash Flow (Quarterly) Chart

View Free Cash Flow (Quarterly) for TBPH.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Free Cash Flow (Quarterly) Chart
Start Trial

Historical Free Cash Flow (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -6.965M
March 31, 2026 73.28M
December 31, 2025 -6.072M
September 30, 2025 -6.508M
June 30, 2025 208.04M
March 31, 2025 43.04M
December 31, 2024 -1.092M
September 30, 2024 -5.211M
June 30, 2024 -4.451M
March 31, 2024 -1.113M
December 31, 2023 -1.531M
September 30, 2023 -2.507M
June 30, 2023 -13.29M
March 31, 2023 -12.16M
December 31, 2022 -124.32M
September 30, 2022 -22.08M
June 30, 2022 -14.84M
March 31, 2022 -26.32M
December 31, 2021 -42.88M
September 30, 2021 -46.48M
June 30, 2021 -50.27M
March 31, 2021 -71.63M
December 31, 2020 -66.17M
September 30, 2020 -79.08M
June 30, 2020 -55.71M
Date Value
March 31, 2020 -56.06M
December 31, 2019 -65.66M
September 30, 2019 -44.70M
June 30, 2019 -48.61M
March 31, 2019 -82.41M
December 31, 2018 -53.68M
September 30, 2018 -50.85M
June 30, 2018 -62.63M
March 31, 2018 47.05M
December 31, 2017 -44.46M
September 30, 2017 -63.12M
June 30, 2017 -45.26M
March 31, 2017 -50.61M
December 31, 2016 -28.51M
September 30, 2016 -12.84M
June 30, 2016 -32.77M
March 31, 2016 -26.99M
December 31, 2015 -34.35M
September 30, 2015 -32.66M
June 30, 2015 -47.32M
March 31, 2015 -57.17M
December 31, 2014 -43.30M
September 30, 2014 -36.84M
June 30, 2014 -51.70M
March 31, 2014 -46.42M

Free Cash Flow Definition

Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.

Read full definition.

Free Cash Flow (Quarterly) Range, Past 5 Years

View Free Cash Flow (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow (Quarterly) Benchmarks

View Free Cash Flow (Quarterly) Benchmarks
Start Trial
Zymeworks, Inc. -31.59M
Viatris, Inc. 328.00M
Ocular Therapeutix, Inc. -70.64M
ANI Pharmaceuticals, Inc. 53.62M
Corcept Therapeutics, Inc. 31.02M